Sang Joon Lee

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

Dae‐Hyun Yoo, Paweł Hrycaj, Pedro C. Miranda et al. · Annals of the Rheumatic Diseases · 2013 · 653 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

Won Park, Paweł Hrycaj, Volodymyr Kovalenko et al. · Annals of the Rheumatic Diseases · 2013 · 604 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study

Won Park, Dae‐Hyun Yoo, Pedro C. Miranda et al. · Annals of the Rheumatic Diseases · 2016 · 229 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +13

Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease

Stefan Schreiber, Shomron Ben‐Horin, Jarosław Leszczyszyn et al. · Gastroenterology · 2021 · 227 citations

Pharmacy, Immunology, Pharmacotherapy +13

Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study

Byong Duk Ye, Marina Pesegova, Olga Alexeeva et al. · The Lancet · 2019 · 209 citations · Full text

Medicine, Clinical Sciences, Immunology +11